Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777557 | 0.79 | TSHR (0.33) | ACHE | |
| SCHEMBL3678973 | 0.78 | AR (0.47) | AR | |
| SCHEMBL9004952 | 0.77 | PTGS1 (0.34) | AR | |
| SCHEMBL262756 | 0.74 | NT5E (0.30) | — | |
| SCHEMBL149760 | 0.74 | TSHR (0.37) | KIF11 | |
| SCHEMBL11272457 | 0.74 | KIF11 (0.39) | KIF11ACHE | |
| SCHEMBL5583736 | 0.74 | AR (0.51) | AR | |
| SCHEMBL5463356 | 0.73 | TSHR (0.40) | KIF11ARKDM4E | |
| SCHEMBL696976 | 0.73 | — | — | |
| SCHEMBL271476 | 0.73 | NT5E (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | claimed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | claimed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | claimed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | claimed |
| CN-116323557-A | Cyclobutylamide monoacylglycerol lipase modulators | 詹森药业有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | claimed |
| EP-1618107-B1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-06-30 | — | — | EP | claimed |
| EP-2186813-A1 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SmithKline Beecham (Cork) Limited (IE) | 2010-05-19 | — | — | EP | claimed |
| EP-1695974-B1 | 1,8-Naphthyridines as CRF antagonists | GLAXO GROUP LTD (GB) | 2010-03-17 | — | — | EP | claimed |
| US-7462622-B2 | Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists | GLAXO GROUP LIMITED (GB) | 2008-12-09 | — | — | US | claimed |
| EP-1200373-A1 | METHOD FOR PRODUCING BIARYLS USING PALLADAPHOSPHACYCLOBUTANE CATALYSIS | Clariant GmbH (DE) | 2002-05-02 | — | — | EP | claimed |
| US-6353136-B1 | SUBSTITUTED ANILINES; ONLY VERY SMALL AMOUNTS OF CATALYST ARE NECESSARY SO COSTS ARE LESS; AMINATING AN AROMATIC HALIDE WITH AN AMINE | CLARIANT GMBH (DE) | 2002-03-05 | — | — | US | claimed |
| EP-1083163-A2 | Catalytic method for the preparation of aromatic amines using a palladaphosphacyclobutane compound as catalyst | Clariant GmbH (DE) | 2001-03-14 | — | — | EP | claimed |
| US-6194627-B1 | REACTING HALOAROMATIC COMPOUND WITH OLEFIN IN PRESENCE OF PALLADIUM COMPOUND AS CATALYST | AVENTIS RESEARCH & TECHNOLOGY GMBH & CO. KG (DE) | 2001-02-27 | — | — | US | claimed |
| WO-2001004076-A1 | METHOD FOR PRODUCING BIARYLS USING PALLADAPHOSPHACYCLOBUTANE CATALYSIS | CLARIANT GMBH (DE) | 2001-01-18 | — | — | WO | claimed |
| US-6084114-A | Dipalladaphosphacyclobutanes and a process for preparing the same | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 2000-07-04 | — | — | US | claimed |
| EP-0938490-A1 | NEW DIPALLADAPHOSPHACYCLOBUTANES AND A PROCESS FOR PREPARING THE SAME | Aventis Research & Technologies GmbH & Co. KG (DE) | 1999-09-01 | — | — | EP | claimed |
| EP-0938459-A1 | PROCESS FOR PREPARING AROMATIC OLEFINS BY USING PALLADAPHOSPHACYCLOBUTANES AS CATALYSTS | Aventis Research & Technologies GmbH & Co. KG (DE) | 1999-09-01 | — | — | EP | claimed |
| WO-1998022412-A1 | PROCESS FOR PREPARING AROMATIC OLEFINS BY USING PALLADAPHOSPHACYCLOBUTANES AS CATALYSTS | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1998-05-28 | — | — | WO | claimed |
| WO-1998022485-A1 | NEW DIPALLADAPHOSPHACYCLOBUTANES AND A PROCESS FOR PREPARING THE SAME | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1998-05-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | CRH, CRHR1, CRHR2 | KIF11 4474/4885AR 267/4885ACHE 2956/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | KIF11 3684/4885AR 1175/4885ACHE 52/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KIF11 3646/4885AR 1147/4885ACHE 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.